Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBIS 3 feasibility study
ISRCTN93764730Phase 3Completed
- Sponsor
- Queen Mary University of London
- Start
- Sep 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of metformin, zoledronic acid, anastrozole, letrozole and exemestane in breast cancer (8 arms), sponsored by Queen Mary University of London. Started Sep 2016; status: completed.
02
Drugs
metforminzoledronic acidanastrozoleletrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN93764730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN93764730.